Mineralocorticoid receptor signaling affects therapeutic effect of enzalutamide

Masaki Shiota, Naohiro Fujimoto, Katuyoshi Higashijima, Kenjiro Imada, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Katsunori Tatsugami, Shunichi Kajioka, Takeshi Uchiumi, Masatoshi Eto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Corticosteroids play important roles in prostate cancer therapeutics. However, their role when combined with enzalutamide remains obscure. Then, we aimed to elucidate the functional and clinical impact of corticosteroids on steroid receptors in androgen receptor (AR)-targeting therapy utilizing enzalutamide. Methods: The therapeutic effect was studied according to concomitant use of corticosteroids in 86 men treated with enzalutamide. The sensitivity to various agents was evaluated using cytotoxicity assays in prostate cancer cells. Gene expression levels were evaluated by quantitative real-time polymerase chain reaction in prostate cancer cells and tissues. Results: The therapeutic effect of enzalutamide was particularly lessened with concomitant treatment with dexamethasone. Consistently, dexamethasone increased cellular resistance to enzalutamide while prednisolone and aldosterone decreased cellular resistance to enzalutamide in prostate cancer cells. Inversely, mineralocorticoid receptor (MR) knockdown augmented the activity of AR signaling and the cellular resistance to enzalutamide. Conclusions: MR plays a critical role in resistance to AR-targeting therapies, which may be overcome by activation of MR signaling.

Original languageEnglish
Pages (from-to)1045-1052
Number of pages8
JournalProstate
Volume78
Issue number14
DOIs
Publication statusPublished - Oct 1 2018

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Mineralocorticoid receptor signaling affects therapeutic effect of enzalutamide'. Together they form a unique fingerprint.

  • Cite this